TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company
Transcenta, biologics, antibody
13 Jan, 2020
It’s been almost two years since the Stock Exchange of Hong Kong (HKG) permitted the public listing of biotech issuers without a track record of profitability. To date, 14 companies in that sector have taken the plunge, of which nine listed in 2019.
Another one to the list looks very likely to be Transcenta. The Suzhou-headquartered biotherapeutics company, which has yet to turn a profit but has raised $230 million in private funding, is aiming for a Hong Kong IPO in around 18 months......